Compare Cipla with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs NOVARTIS - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA NOVARTIS CIPLA/
NOVARTIS
 
P/E (TTM) x 32.2 2,137.4 1.5% View Chart
P/BV x 4.5 28.4 16.0% View Chart
Dividend Yield % 0.5 1.6 28.9%  

Financials

 CIPLA   NOVARTIS
EQUITY SHARE DATA
    CIPLA
Mar-20
NOVARTIS
Mar-19
CIPLA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs586980 59.7%   
Low Rs357600 59.4%   
Sales per share (Unadj.) Rs207.0198.7 104.2%  
Earnings per share (Unadj.) Rs18.621.0 88.7%  
Cash flow per share (Unadj.) Rs33.222.3 149.0%  
Dividends per share (Unadj.) Rs4.0010.00 40.0%  
Dividend yield (eoy) %0.81.3 67.1%  
Book value per share (Unadj.) Rs195.5307.5 63.6%  
Shares outstanding (eoy) m806.3524.69 3,265.9%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.34.0 57.2%   
Avg P/E ratio x25.337.7 67.2%  
P/CF ratio (eoy) x14.235.5 40.0%  
Price / Book Value ratio x2.42.6 93.8%  
Dividend payout %21.547.7 45.1%   
Avg Mkt Cap Rs m379,91219,508 1,947.5%   
No. of employees `00025.80.6 4,448.4%   
Total wages/salary Rs m30,2701,171 2,584.8%   
Avg. sales/employee Rs Th6,459.68,445.4 76.5%   
Avg. wages/employee Rs Th1,171.22,015.7 58.1%   
Avg. net profit/employee Rs Th580.2891.0 65.1%   
INCOME DATA
Net Sales Rs m166,9494,907 3,402.4%  
Other income Rs m3,442783 439.8%   
Total revenues Rs m170,3915,689 2,994.9%   
Gross profit Rs m32,060123 26,107.4%  
Depreciation Rs m11,74732 36,938.7%   
Interest Rs m1,97416 12,412.6%   
Profit before tax Rs m21,782858 2,539.6%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,312340 1,856.5%   
Profit after tax Rs m14,995518 2,896.5%  
Gross profit margin %19.22.5 767.3%  
Effective tax rate %29.039.6 73.1%   
Net profit margin %9.010.6 85.1%  
BALANCE SHEET DATA
Current assets Rs m117,0388,055 1,453.1%   
Current liabilities Rs m43,9311,850 2,374.5%   
Net working cap to sales %43.8126.4 34.6%  
Current ratio x2.74.4 61.2%  
Inventory Days Days9645 212.6%  
Debtors Days Days8534 250.9%  
Net fixed assets Rs m107,424150 71,711.5%   
Share capital Rs m1,613123 1,306.7%   
"Free" reserves Rs m156,0187,469 2,089.0%   
Net worth Rs m157,6307,592 2,076.3%   
Long term debt Rs m23,6930-   
Total assets Rs m236,6269,824 2,408.6%  
Interest coverage x12.054.9 21.9%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.5 141.3%   
Return on assets %7.25.4 132.0%  
Return on equity %9.56.8 139.5%  
Return on capital %12.811.5 111.6%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03658 97,284.7%   
Fx outflow Rs m6,7641,326 510.0%   
Net fx Rs m49,272-1,269 -3,883.7%   
CASH FLOW
From Operations Rs m30,685-1,943 -1,579.4%  
From Investments Rs m1,0402,742 37.9%  
From Financial Activity Rs m-29,488-298 9,888.7%  
Net Cashflow Rs m2,340501 466.8%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 75.0 27.7%  
Indian inst/Mut Fund % 12.2 2.0 610.0%  
FIIs % 23.7 1.6 1,481.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 21.5 121.9%  
Shareholders   161,166 41,647 387.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT PHARMOVA   DIVIS LABORATORIES  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

RBI's Relief Measures Amid Covid, 5G Trials by Mobile Operators, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed positive trading activity throughout the day yesterday and ended higher.

Related Views on News

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Power Grid's InvIT IPO: Key Points to Consider(Company Info)

Apr 23, 2021

In this article, we discuss the key reasons why the stock of Power Grid was in focus today.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


May 5, 2021 (Close)

TRACK CIPLA

CIPLA - NEULAND LABS COMPARISON

COMPARE CIPLA WITH

MARKET STATS